BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the details of its worldwide Direct Response Television (DRTV) strategy to further enhance its international marketing efforts for its award-winning, pain relieving ActiPatch and Allay brands. The Company will launch campaigns in Latin America beginning in December, Canada in January, Europe and Australia in the first quarter and is currently in process of negotiating a partnership to enter the lucrative Japanese market.
BioElectronics plans to launch its first international DRTV campaign in Latin America during mid-December and has selected one of the largest full-service direct response companies specializing in the Hispanic market. "We are very excited to be launching our first television advertising within the Latin American market in conjunction with RC Television Production, Inc. (www.rctelevision.com), which is one of the leading DRTV firms in Latin America," commented Andrew Whelan, CEO of BioElectronics. "Over the past few years the size of the international Hispanic DRTV market has grown considerably and we believe our ActiPatch and Allay brands will be very well received. Over the next few weeks millions of consumers within Latin America will begin seeing our advertising on some of the region's largest television networks. Our initial media purchases have been completed and our call center and fulfillment functions have now been set up. While our first Hispanic-oriented campaigns will mainly target the larger companies in South America, we are also excited about the U.S. domestic Hispanic market, which at 45.5 million strong, is the single largest and fastest growing minority group in the United States."
BioElectronics recently contracted with industry leading DRTV firm Schulberg MediaWorks (www.smw.tv) for the production of several DRTV spots targeted at the English speaking world, including 60-second and 120-second spots for both the Allay and ActiPatch brands and a five minute international-oriented ActiPatch version. The first of these spots can now be viewed at the Company's website at www.bielcorp.com. "We are very pleased with the quality of media we have produced that will target the English speaking world," commented Mr. Whelan. "We plan to launch our first campaigns in Canada during the month of January and we are currently working with media buyers in the United Kingdom and Australia for campaigns beginning during the first quarter of 2010. The experience we will gain in these geographies will be important as we prepare to launch similar efforts in the United States as soon as FDA clearance is granted."
BioElectronics believes these campaigns, in addition to other international marketing programs currently being negotiated, which include Japan and China, will generate substantial revenue growth for the Company during 2010.
Triptans better at relieving migraine pain than recently marketed and more expensive drugs